Move Over Xanax? New Research on LSD Offers Hope for Anxiety https://www.psychologytoday.com/us/...x-new-research-on-lsd-offers-hope-for-anxiety
PUBMED - Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial - https://pubmed.ncbi.nlm.nih.gov/40906494/
Reimagining LSD to Treat Mental Health Disorders - https://themedicinemaker.com/issues...agining-lsd-to-treat-mental-health-disorders/
(Video) Trial shows promise for treating anxiety with LSD https://www.10news.com/news/local-news/trial-shows-promise-for-treating-anxiety-with-lsd
MindMed Corporate Presentation - October 2025 https://d1io3yog0oux5.cloudfront.ne...f/MindMed+Corporate+Presentation_Oct+2025.pdf 1. Company Overview Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company developing psychedelic-inspired medicines to treat psychiatric and neurodevelopmental disorders, with a focus on generalized anxiety disorder (GAD) and major depressive disorder (MDD) — two of the largest drivers of psychiatric disease burden. Lead asset: MM120 ODT (Lysergide D-tartrate) — an orally disintegrating tablet version of LSD, now in Phase 3 trials for GAD and MDD. Secondary asset: MM402 (R-(-)-MDMA) — a proprietary MDMA enantiomer being advanced for autism spectrum disorder (ASD). Cash position: $209.1 million (as of Sept 30, 2025) with a runway into 2027, and an additional $120 million credit facility. 2. MM120 Program Highlights Clinical Progress Three Phase 3 readouts expected in 2026: GAD (two studies: MM120-300 and MM120-301) MDD (one study: MM120-310) Phase 3 design mirrors successful Phase 2b results, which showed: Rapid and durable anxiety reduction after a single dose Large effect size (Cohen’s d = 0.81), more than double standard GAD treatments 48% remission at 12 weeks Favorable tolerability with mostly transient, mild-to-moderate adverse events Regulatory Status Breakthrough Therapy Designation (U.S. FDA) Innovation Passport (U.K. MHRA) Phase 3 protocols aligned with FDA guidance for psychedelic drug development Comparative Efficacy MM120’s single-dose 12-week effect surpassed leading SSRIs/SNRIs like Duloxetine, Escitalopram, and Venlafaxine in historical HAM-A improvement data. No psychotherapy is required — the observed benefit was a standalone drug effect. 3. Market Opportunity Unmet Need 26 million U.S. adults live with GAD; 41 million with MDD. >50% fail first-line pharmacological therapy. Existing options have slow onset, poor efficacy, and low tolerability (sexual dysfunction, weight gain, dependency). Commercial Potential MM120 could deliver: Fast onset and durable response Intermittent dosing reducing long-term side effects Single-session treatment model (5–8 hours, outpatient setting) If approved, MM120 could access billion-dollar markets in both GAD and MDD. Reimbursement & Delivery Fits within existing psychiatric care infrastructure. Reimbursement anticipated via existing CPT codes for psychedelic therapy monitoring. Potential 56× fewer administration sessions and 14× fewer monitoring hours per year vs. Spravato® (esketamine). 4. MM402 (R-(-)-MDMA) Program Completed Phase 1 in 2024 — well-tolerated up to 255 mg. Phase 2a study in autism spectrum disorder (ASD) to begin Q4 2025, exploring effects on social and communication symptoms. ASD prevalence: ~1 in 31 U.S. children; no approved treatments for core symptoms. 5. Financial Summary & Outlook Metric Detail Cash & Investments $209.1 M (Sept 30 2025) Credit Facility Up to $120 M ($42 M drawn) Shares Outstanding 75.8 M (June 30 2025) Operating Expenses (Q2 2025) $40.9 M (R&D $29.8 M / G&A $11.1 M) Cash Runway Funding operations into 2027 Upcoming Catalysts Three Phase 3 topline readouts in 2026; MDD Phase 3 initiation mid-2026 6. Strategic Takeaways Strong execution: successful end-of-Phase 2 meeting with FDA; robust IP protection through 2041. Clinical ambition: potential first-in-class psychedelic-derived oral therapy for anxiety and depression. Commercial readiness: scalable delivery model, existing infrastructure, and positive economics for providers. Outlook: if MM120 achieves expected Phase 3 outcomes, MindMed could become a leader in next-generation psychiatric therapeutics with first-mover advantage in both GAD and MDD.
Minnesota Psychedelic Medicine Task Force LEGISLATIVE REPORT https://www.lrl.mn.gov/docs/2024/mandated/241756.pdf MindMed's study is listed in this document - State's are watching and gearing up... Hold. --- Executive summary The Minnesota legislature created the Psychedelic Medicine Task Force to advise it on the legal, medical, and policy issues associated with the legalization of psychedelic medicine in the state. Within that legislation and this report, “psychedelic medicine” means 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and psilocybin, which can be synthetic or with psilocybin, found naturally in certain mushrooms (often referred to as “magic mushrooms”). The task force met once a month between November 2023 and December 2024 to discuss the scientific, cultural, and legal considerations of the legislative charge, as well as questions of cost, access, and equity. Smaller working groups also met outside of the larger monthly meeting. The task force regularly consulted subject matter experts, both during full task force meetings and working groups. The report this task force produced is a product of the shared perspectives and experiences of its appointed members, and not of any one individual nor of any of the state agencies that served on it. Recommendations By a two-thirds supermajority vote of its members, the task force recommends the Minnesota legislature: 1. Create a state-regulated clinical program for the therapeutic administration of psilocybin-containing mushrooms. 2. Remove criminal penalties for the personal use and possession of psilocybin-containing mushrooms. 3. Allocate funding for more research into the health benefits of MDMA, psilocybin, and LSD. The task force considered additional proposals that did not reach a two-thirds supermajority, including: 1. The removal of criminal penalties for the personal use and possession and noncommercial (without remuneration) cultivation and sharing of psilocybin-containing mushrooms. 2. Remove criminal penalties for the personal use and possession of MDMA, synthetic psilocybin, and LSD. 3. The creation of a state-regulated program for the clinical administration of MDMA and LSD. 4. Creating a regulated, adult use market for psilocybin-containing mushrooms.
Vendor Dispute from 2024 Turns into a Win for MindMed https://www.govinfo.gov/content/pkg...v-00709/pdf/USCOURTS-paed-2_24-cv-00709-0.pdf There was a court filing made mid last year I just uncovered involving Signant Health and EMA Wellness could actually be a mild positive for MindMed. See the attached link. The dispute was between two vendors competing for MindMed’s Phase III clinical trial work... Not against MindMed itself! (I need to disclaim that because people misconstrue statements or informaiton). The judge denied Signant’s request to stop EMA from working with MindMed, finding no evidence of trade secret misuse or wrongdoing, and even accepted MindMed’s statement that Signant was never in contention for the contract. This outcome clears the way for MindMed’s clinical trial to continue without disruption, validates that the company managed its vendor relationships properly, and suggests its program is valuable enough to spark competition among major trial service providers. In short, MindMed was just the prize these vendors were fighting over, and the court’s ruling removes any legal overhang while confirming business as usual. A quietly bullish development for shareholders. MindMed was in demand as a client. Two specialized clinical-trial technology firms (Signant and EMA) were competing for its business. That suggests MindMed’s Phase III program is viewed as valuable and high-profile within the industry. Vendors don’t fight over small, low-potential clients. The court validated MindMed’s independence. MindMed was not implicated in wrongdoing, and the judge accepted MindMed’s statement that it made an independent decision to award the contract to EMA. That protects MindMed from any legal entanglement and shows it’s managing its vendor relationships cleanly. EMA can now focus on execution. The injunction denial means EMA’s work for MindMed can continue uninterrupted. Regulatory delays or disruptions to trial data collection are avoided — which is key for investor confidence. MindMed likely got more leverage. Vendor competition often leads to better pricing, service levels, and innovation for the client. If Signant and EMA were fighting to prove who could deliver better eCOA tools, MindMed might have benefited from improved technology or lower costs.
MindMed to Participate in Upcoming Investor Conferences NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: https://www.businesswire.com/news/home/20251105303331/en
$MNMD Ordinary Unhappiness 121: LSD: Subjectivity, Ineffability, and Mental Health feat. Dan Karlin https://ordinaryunhappiness.buzzspr...neffability-and-mental-health-feat-dan-karlin Abby and Patrick continue their series on psychedelics via an in-depth interview with Dr. Dan Karlin. Karlin is a psychiatrist and Chief Medical Officer at MindMed, where he oversees clinical trials using LSD to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). Karlin first fills Abby and Patrick in about those disorders, MindMed’s ongoing clinical trials, and both the history of LSD research and potential near-future therapeutic applications. In the wide-ranging conversation that follows, they explore provocative questions about the relationship between quantitative research and qualitative description, the challenges of thinking simultaneously about neurobiology and phenomenology, and how various models fall short in different ways when it comes to describing ineffable experiences. They also probe what Karlin’s work suggests about the ways bodily perceptions, metaphors, and narrative shape our subjective sense of self, how the symptoms of MDD and GAD can be seen in that light, and how certain psychedelics may work to rapidly reorganize those underlying patterns and configurations in ways that mirror the work of long-term therapy. Note: All opinions are Karlin's own and not attributable to MindMed
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Abstract A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual. Inventors: MACK; Peter (Chapel Hill, NC), TRENKTROG; Timm (Binningen, CH), MELTON; Dustin (Melbane, NC), DOTY; Bethany Amber (Clayton, NC), SCHROEDER; Jon (Madison, WI), GARRETT; Lisa Marie (Swindon, GB) Applicant: Mind Medicine, Inc. (New York, NY) Family ID: 85239753 Appl. No.: 19/276575 Filed: July 22, 2025 https://ppubs.uspto.gov/api/patents...2LTRkZWQtYjA1ZS1mNTZmM2FjN2U1MTciLCJleHAiOjB9
MindMed's Molecule Engine Patent - Understanding: ALLYL-AND PROPARGYLAMINE-TYPE PHENETHYLAMINES AND TRYPTAMINES FOR TREATING MEDICAL DISORDERS - Patent Application (20250312309) MindMed Patent 20250312309 — Plain-English Investor Summary TXT - https://ppubs.uspto.gov/api/patents...2LTRkZWQtYjA1ZS1mNTZmM2FjN2U1MTciLCJleHAiOjB9 PDF - https://ppubs.uspto.gov/api/pdf/dow...2LTRkZWQtYjA1ZS1mNTZmM2FjN2U1MTciLCJleHAiOjB9 MindMed has filed a major patent covering an entirely new class of psychedelic-inspired medicines built from modified phenethylamines and tryptamines. These compounds use allyl and propargylamine groups to create innovative molecules that can deliver the therapeutic benefits of psychedelics or MDMA with fewer side effects, shorter duration, smoother experiences, or even without a “trip” at all. What this patent really represents is a MOLECULE ENGINE. A platform that allows MindMed to generate many next-generation therapeutics with tunable properties. Instead of a single drug, this is a chemical space from which dozens of future candidates can be derived. The goal is to overcome the biggest limitations of current psychedelic-assisted therapies: long sessions, unpredictable intensity, adverse reactions, cardiovascular stress, nausea, and the fact that not all patients tolerate psilocybin, LSD, MDMA, or DMT. These new molecules are designed to be safer, cleaner, shorter-acting, and more predictable while still producing therapeutic outcomes through 5-HT2A (activity similar to psychedelics), monoamine release/transport effects (activity similar to MDMA), MAO inhibition, or neuroplasticity. Importantly, some of these compounds may produce cognitive or mood benefits WITHOUT a hallucinogenic experience. Meaning they could be positioned as fast-acting antidepressants or anxiety treatments that don’t require a full psychedelic session. Others may mimic the best parts of MDMA or psilocybin but with improved tolerability and lower risk. The patent covers: multiple families of novel chemical structures (dozens to hundreds) all isomers, enantiomers, salts, and prodrugs use for treating a very wide range of conditions (PTSD, depression, anxiety, addiction, autism-related issues, pain conditions, personality disorders, Parkinson's symptoms, and more) mechanisms that allow session shortening, reduced side effects, and more scalable clinical models This is a broad chemical-matter patent that effectively secures the entire molecular neighborhood, blocking competitors and establishing MindMed’s long-term defensibility. The company is not just improving existing psychedelics. It is engineering precision-tailored molecules that address real-world medical needs and payer-friendly treatment models. This filing signals that MindMed is thinking far beyond MM120 and MM402. It is building a next-generation psychedelic medicine platform, a true molecule engine. capable of producing safer, more targeted, and more scalable therapeutics for the future. For long-term holders, this is the type of foundational IP that expands the pipeline, deepens competitive moat, and positions the company for multiple future drug programs.
Key Takeaways 1) Strong, broad patents can absolutely transform a company’s economics. AbbVie (Humira), Gilead (Sovaldi/Harvoni), Vertex (CFTR modulators), and Biogen (Tecfidera) all used composition-of-matter / platform-style IP to secure multi-year periods of limited competition and very high margins. 2) The biggest upside comes when the patent doesn’t just cover “a drug” but a *molecular neighborhood* a true molecule engine. Vertex’s CFTR franchise and Gilead’s HCV backbone are perfect examples of how one chemical scaffold/platform can support multiple products, combinations, and label expansions while staying inside the same core IP. 3) MindMed’s new allyl-/propargyl-phenethylamine and tryptamine patent looks like an early version of that playbook in the psychedelic/psych-neuro space: a tunable family of molecules with protected chemistry plus broad use claims. If even one or two of these compounds mature into successful drugs, the *entire* family’s IP becomes strategically important, and that’s where real moat + multiple-program upside starts to resemble the examples above. 4) None of this guarantees success — clinical data, regulators, and execution still drive outcomes but structurally, MindMed is laying down the kind of IP foundation that has historically enabled some of the biggest winners in biotech once the biology proves out.
MindMed Patent 20250345323 — Orally Disintegrating LSD (ODT) Plain-English Investor Summary TXT: https://ppubs.uspto.gov/api/patents...2LTRkZWQtYjA1ZS1mNTZmM2FjN2U1MTciLCJleHAiOjB9 PDF: https://ppubs.uspto.gov/api/pdf/dow...2LTRkZWQtYjA1ZS1mNTZmM2FjN2U1MTciLCJleHAiOjB9 This patent protects MindMed’s creation of a pharmaceutical-grade, orally disintegrating LSD tablet (ODT) produced through a lyophilization process. Historically, LSD has only been administered as liquids or blotter paper, both of which are unstable, difficult to standardize, and not commercially scalable. MindMed’s formulation solves the biggest barriers to pharmaceutical LSD by offering a stable, consistent, microgram-accurate dosage form suitable for large clinical trials and eventual global commercialization. The innovation is not simply “LSD in tablet form,” but a manufacturing method that ensures uniformity and long-term stability — two challenges that have held LSD back from becoming a viable therapeutic product. By flash-freezing a stock solution of LSD and excipients and then lyophilizing it in pre-formed molds, MindMed produces an ODT that dissolves in the mouth within 60 seconds, shows minimal chemical degradation under accelerated stability testing, and meets modern regulatory requirements for precision dosing. No commercially viable immediate-release LSD tablet existed before this, and no ODT version is reported in literature. The patent creates a significant moat by covering the tablet, the method of manufacturing it, the excipient ranges, the lyophilization process, the use of LSD in specific salt forms (especially d-LSD tartrate), and the therapeutic application of this ODT across a wide range of psychiatric and neurological conditions such as anxiety, depression, headache disorders, addiction, PTSD, neurodegenerative diseases, autism spectrum disorders, and pain. This effectively gives MindMed control over the pharmaceutical ODT format most suitable for scalable therapeutic use. Strategically, this moves LSD far beyond research-only formats into a mass-manufacturable, shelf-stable, patient-friendly dosage form that enables consistent pharmacokinetics, pre-gastric absorption (improving bioavailability), and easier dosing in elderly, pediatric, and dysphagic populations. It also eliminates the cold-chain and logistical complexities associated with LSD solutions, allowing MindMed to build a global commercial supply chain similar to modern oral therapies. Bottom line: This patent is about owning the commercially viable format of medical LSD. Just as many blockbuster drugs have succeeded due to formulation innovations (fast-dissolve tablets, stabilized salt forms, controlled-release technologies), MindMed now holds foundational IP that transforms LSD into a scalable, pharmaceutically robust product. For long-term investors, this strengthens regulatory readiness, protects future revenue opportunities, and builds a durable competitive moat in LSD-based therapeutics.
Quietly filling the PSILOs - Understanding - FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY Patent Application (20250205196) This was filed mid year, but had remained undisclosed and not talked about, but is very important. MindMed quietly filed a major patent on stabilized psilocin, not psilocybin, despite never publicly discussing psilocin in their pipeline. This patent is essentially a land-grab for every practical, pharmaceutical-grade way to make psilocin stable enough to be an actual drug. TXT: [https://ppubs.uspto.gov/api/patents...LTQyNWUtYTEyZi01NzhjZTUyN2RjMzciLCJleHAiOjB9) PDF: [https://ppubs.uspto.gov/api/pdf/dow...LTQyNWUtYTEyZi01NzhjZTUyN2RjMzciLCJleHAiOjB9) # What the Patent Is A sweeping patent covering: # 1. Stabilized Psilocin The entire purpose of the patent is creating **stable pharmaceutical forms** of psilocin (the active drug in magic mushrooms). Psilocin is normally: * chemically unstable * degrades in water, air, heat, and light * unusable as a drug unless stabilized The patent solves this. # 2. Dozens of Psilocin Salt Forms MindMed claims stable salt forms including: * tartrate (multiple forms: Tar1, Tar2) * fumarate * succinate * lactate * malonate * glutarate * benzoate * besylate * oxalate * phosphate * and many more Some are crystalline, amorphous, or hydrates. This alone is a huge IP stake. # 3. Stabilizing Additives MindMed also claims using: * antioxidants (ascorbic acid, BHT, etc.) * photostabilizers (UV blockers, dyes, opacifiers) * coatings and tablet films * formulations that prevent oxidation and light degradation * nanoparticle and liposomal formulations Any company that tries to stabilize psilocin using these methods could run into this patent. # 4. Every Administration Route The patent covers psilocin in: * pills/capsules * oral liquids * injectables (IV/IM/SC) * nasal sprays * films (oral/buccal/sublingual) * inhalation * patches * nanoparticles * liposomes Basically *any* way you could deliver psilocin as a drug. # 5. All Therapeutic Uses They broadly list every major indication psilocybin is being researched for, including: * depression (including TRD) * anxiety * PTSD * addiction (alcohol, nicotine, opioids, stimulants) * OCD * pain & headaches (cluster, migraine) * neurodegenerative diseases * autism spectrum disorders This is typical for pharmaceutical IP — broad claim coverage. # What the Patent Is NOT # 1. Not a Psilocybin Patent MindMed explicitly argues: * psilocybin is expensive to make * it is a prodrug (inactive until converted) * it shows high variability between patients * its manufacturing scale is limited * psilocin is the true active drug They are positioning psilocin as *superior* to psilocybin. # 2. Not a Public Pipeline Asset MindMed has *never* publicly disclosed a psilocin program. But this patent is signed by: * CEO Robert Barrow, and * multiple senior MindMed scientists So internally, they clearly consider this strategically important. # Why Would MindMed File This Without Talking About It? # 1. IP Land-Grab This patent attempts to control: * all stable forms of psilocin * all routes of administration * all stabilizing techniques * all therapeutic uses This is foundational IP — very valuable even if they aren’t developing the drug yet. # 2. Psilocin Has Key Advantages Over Psilocybin If you can stabilize psilocin, you get: * immediate activity (no prodrug conversion) * far more predictable dosing * lower variability between patients * simpler, cheaper synthesis * easier scaling to pharmaceutical manufacturing Psilocybin has *multiple known problems*. Psilocin avoids all of them *if stabilized*. # 3. Defensive Strategy Even if MindMed never sells psilocin themselves: * This patent can block competitors * They can license it * They can partner it * They can hold it for future development * It could be a tool for M&A leverage Companies often patent long before revealing pipeline plans. # In Plain English MindMed filed a patent that basically says: > They now hold IP around: * salt forms * formulations * delivery methods * stability methods * polymorphs * therapeutic indications It is extremely broad. # What This Suggests Even though MindMed doesn’t publicly discuss psilocybin/psilocin, the patent is strong evidence of: * internal strategic interest * future-proofing for psilocin’s commercialization * potential pivot into next-generation psychedelics * positioning for when psilocybin patents expire * creating a moat around the *active* psychedelic compound It is a serious and deliberate move...
